慢性淋巴细胞白血病的分子发病机制
该综述讨论慢性淋巴细胞白血病(CLL)的分子特征,指出多数患者呈惰性病程但部分快速进展,且无单一统一致病病变。近期研究显示免疫球蛋白重链突变状态可预测一线化学免疫治疗的持久缓解,复杂核型比TP53缺失更能预测伊布替尼和维奈克拉治疗的不良反应。
要点
- CLL以成熟CD5阳性B淋巴细胞克隆性增殖为特征。
- 免疫球蛋白重链突变状态预测一线化学免疫治疗持久缓解。
- 复杂核型比TP53缺失更强预测伊布替尼和维奈克拉治疗不良反应。
核心结论
- CLL无单一统一致病病变,但分子特征可用于患者风险分层。
研究设计与样本
- 综述,讨论CLL分子特征及技术进展在风险分层中的应用。
主要发现
- 多数CLL患者呈惰性临床病程,部分患者快速疾病进展。
- 免疫球蛋白重链突变状态预测一线化学免疫治疗的持久缓解。
- 复杂核型比TP53缺失更强预测伊布替尼和维奈克拉治疗的不良反应。
临床怎么用
- 可根据免疫球蛋白重链突变状态和复杂核型等分子特征对CLL患者进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal expansion of mature, CD5 positive, B lymphocytes in the blood, marrow, lymph nodes and spleen. For the majority of patients, CLL follows an indolent clinical course, while a proportion of patients experience rapid disease progression. Despite the strong correlation between certain genetic defects and prognosis, there remains no single unifying pathogenic lesion in CLL. With recent advances in therapy it is increasingly important to stratify CLL patients according to risk. This has been highlighted by two recent studies, the first showing that immunoglobulin heavy chain mutational status predicts a durable response to frontline chemoimmunotherapy and the second showing that complex karyotype is a stronger predictor of poor response to ibrutinib and venetoclax therapy than TP53 deletion. In this review we discuss the molecular features of CLL and how technological advances can identify patient subsets and stratify them according to risk.
引用
- Crassini K, Stevenson WS, Mulligan SP, et al. Molecular pathogenesis of chronic lymphocytic leukaemia. Br J Haematol. 2019. PMID: 31364161. doi:10.1111/bjh.16102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。